HL7 FHIR® Pharmaceutical Quality

Drug Substance Stability Study

Stelbatolol — ICH CTD Section 3.2.S.7

Study ID: PLO555
Status: Final
Duration: 36 months
Start: 2019-09-08

Storage Conditions

Long-Term 30°C / 65% RH
Accelerated 40°C / 75% RH

Study Conclusion

The retest period can be 36 months

Test Scope

Description
Assay
Impurities
Particle Size

Study Protocol Schedule

Condition Initial 3 mo 6 mo 9 mo 12 mo 18 mo 24 mo 36 mo
Long-Term
30°C/65% RH
XY X X X X X X (X)
Accelerated
40°C/75% RH
XY X X

X = Description + Assay + Impurities   |   Y = Particle Size Distribution   |   (X) = Optional Testing

Assay Trends — Long-Term 30°C/65% RH

Assay (% w/w)
102% 101% 100% 99% 98% Initial 18 months 36 months Upper Limit (102.0%) Lower Limit (98.0%) 100.1% 100.0% 99.8%

Stability Results

Test Acceptance Criteria Initial (CAT1) Initial (CAT2) Initial (CAT3) 36m (CAT1) 36m (CAT2) 36m (CAT3)
Description A white to brown powder Complies Complies Complies Complies Complies Complies
Assay 98.0 – 102.0% w/w 100.1 100.2 99.9 99.8 99.7 99.9
Total Impurities ≤ 1.5% w/w 0.10 0.12 0.11 0.35 0.38 0.31
Particle Size (d50) ≤ 200 μm 145 152 148 NT NT NT
Test Acceptance Criteria Initial (CAT1) Initial (CAT2) Initial (CAT3) 6m (CAT1) 6m (CAT2) 6m (CAT3)
Description A white to brown powder Complies Complies Complies Complies Complies Complies
Assay 98.0 – 102.0% w/w 100.1 100.2 99.9 99.5 99.4 99.6
Total Impurities ≤ 1.5% w/w 0.10 0.12 0.11 0.45 0.48 0.41

FHIR Resource Explorer

▼ 📄 DiagnosticReport 1 resource
▼ 📋 PlanDefinition 1 definition
▶ ⚙️ ActivityDefinition 11 activities
📄 ActivityDefinition/10d7b693-7a0e-2f71-9a10-642e5a0a5d42
📄 ActivityDefinition/480a61f8-14b3-233e-8e5f-7f0db9696a1e
📄 ActivityDefinition/bee486c4-6ab5-6293-4114-d4be24f303d3
📄 ActivityDefinition/99893d3c-520c-8d7b-6d73-f46b1a662201
📄 ActivityDefinition/b3254b8e-6fc3-88d3-7d38-0afcf13c4f67
📄 ActivityDefinition/c9b53a46-2f61-7b3f-5780-5f5c79a47f12
📄 ActivityDefinition/d6f7de9d-57a5-6a2c-1c2f-0d65718860f2
📄 ActivityDefinition/75073965-82eb-407d-34cf-3a7767a38149
📄 ActivityDefinition/1b43a536-3c29-3427-0b93-e35866ef8495
📄 ActivityDefinition/8a453cd8-1ac3-4c86-48c3-3e5ea9ee76a9
📄 ActivityDefinition/cf2f00df-971f-0bab-8768-4251b1ad0817
▶ 📐 ObservationDefinition 8 definitions
📄 ObservationDefinition/18762cff-9e29-6e71-1184-e9202fee8cba
📄 ObservationDefinition/559ffdc3-349b-a4a3-a651-ce2715f08d69
📄 ObservationDefinition/7943795a-2abe-666f-545f-133e23b97119
📄 ObservationDefinition/73d9d304-a0b8-31b6-1165-346563b9305e
📄 ObservationDefinition/31abea79-81da-17f8-9d8c-94e9bb75876e
📄 ObservationDefinition/6b96124b-1a44-0b6b-6783-d6c49360230b
📄 ObservationDefinition/35fa7b97-98d3-35d3-5672-4ab1047d57fc
📄 ObservationDefinition/accb8802-4223-61e2-8c79-2282e22a2bb6
▼ 🧪 Specimen 7 samples
▶ 📦 SpecimenDefinition 2 definitions
📄 SpecimenDefinition/643d8b44-71f4-2b58-07e8-51c22b294b25
📄 SpecimenDefinition/306637ec-1041-80e8-8e77-e7ca814253e1
▶ 📊 Observation 7 Observations
📄 Observation/588a6787-0454-55ef-0b8a-4c8941b6976c
📄 Observation/930c7f69-2546-7148-2069-b3be3a755edf
📄 Observation/8070745c-30c4-a52e-41fd-600a913578d4
📄 Observation/f16113fe-27e7-0aa2-6787-9415f5051900
📄 Observation/1b25eb25-9149-02f6-9676-c87f90c64904
📄 Observation/004ed877-7729-834e-3b6b-a2cf4bdb2377
📄 Observation/f958e1e9-6023-4e39-2ffe-a9c8f135a2dd
▶ 🏢 Organization 4 resources
📄 Organization/62c1b1b4-8d15-26d2-57f9-25a2f60b6181
📄 Organization/6049d921-9935-90b7-4efc-894a66483c00
📄 Organization/e2359a4e-3091-23f8-2242-87e701830d55
📄 Organization/378fbe5f-5926-3a5c-4c64-5428df877b08
▶ 💠 Substance 3 resources
📄 Substance/a3fdc23b-6c16-2e65-481e-3fc895b37b87
📄 Substance/cbcecab6-374c-396f-29be-877da7285e8d
📄 Substance/ae1f3b4c-4f14-1460-6903-7260959ea2cd
▼ 🧪 Specimen 7 samples
▶ 📦 SpecimenDefinition 2 definitions
SpecimenDefinition/643d8b44-71f4-2b58-07e8-51c22b294b25
SpecimenDefinition/306637ec-1041-80e8-8e77-e7ca814253e1
▶ 📊 Observation 7 Observations
Observation/588a6787-0454-55ef-0b8a-4c8941b6976c
Observation/930c7f69-2546-7148-2069-b3be3a755edf
Observation/8070745c-30c4-a52e-41fd-600a913578d4
Observation/f16113fe-27e7-0aa2-6787-9415f5051900
Observation/1b25eb25-9149-02f6-9676-c87f90c64904
Observation/004ed877-7729-834e-3b6b-a2cf4bdb2377
Observation/f958e1e9-6023-4e39-2ffe-a9c8f135a2dd
▶ 🏢 Organization 4 resources
Organization/62c1b1b4-8d15-26d2-57f9-25a2f60b6181
Organization/6049d921-9935-90b7-4efc-894a66483c00
Organization/e2359a4e-3091-23f8-2242-87e701830d55
Organization/378fbe5f-5926-3a5c-4c64-5428df877b08
▶ 💠 Substance 3 resources
Substance/a3fdc23b-6c16-2e65-481e-3fc895b37b87
Substance/cbcecab6-374c-396f-29be-877da7285e8d
Substance/ae1f3b4c-4f14-1460-6903-7260959ea2cd
▼ 🧪 Specimen 32 samples
▶ 📦 SpecimenDefinition 2 definitions
▶ 📊 Observation 204 Observations
▶ 🏢 Organization 2 resources
▶ 💠 Substance 3 resources

Related Module 3 Documents

3.2.S.1.3 General Properties

Property Value
Appearance White to slightly yellow powder
Solubility (Purified Water, PhEur) Freely soluble (23 - 27 mg/mL)
Solubility (Acetone, PhEur) Slightly soluble (2 - 3 mg/mL)
Solubility (Ethanol, PhEur) Soluble (15 - 17 mg/mL)
pH in aqueous solution 6.7 - 6.8 (10 mg/ml at 25°C)
Hygroscopy Hygroscopic
Stereochemistry One asymmetric center and one axis of chirality; (S,M) - enantiomer

3.2.S.4.1 Specification

Test Parameter Method Acceptance Criteria
Description Visual inspection A white to brown powder
Identification Identification by IR spectroscopy / HPLC Conforms with reference
Assay Assay by LC 98% to 102% w/w
Drug Substance Related Organic Impurities Organic impurities by LC Total impurities ≤ 2.0% w/w
Mutagenic Impurities Impurity 5 content by LC-MS ≤ 50 ppm
Enantiomeric Purity Enantiomeric purity by LC ≥ 99.6%
Residual Solvents Residual solvents by headspace GC Solvent 1 ≤ 0.1% w/w, Solvent 2 ≤ 2.0% w/w
Water Content USP Karl Fischer titration ≤ 1.0% w/w
Particle Size Distribution Laser diffraction D(v,0.9) ≤ 319 µm, D(v,0.5) ≤ 145 µm, D(v,0.1) ≤ 20 µm

Resource Detail

Resource Detail